Xenikos

logo Xenikos
Website: www.xenikos.com
Organisatietype: Bedrijf
Specialisatie: Biotechnologie, Farma
KvK nummer: 9206362
Careers: Jobs

Adres

finance@xenikos.com
6524 AL
Nijmegen
Nederland

Social

Xenikos1

Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.

Introducing T-Guard®

T-Guard® is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, acute graft-versus-host disease (aGVHD), solid-organ rejection and several severe autoimmune diseases.

Afbeelding van Marc Kalf

Is dit bedrijf voor jou een potentiële match? Neem dan contact op met:

Marc Kalf National ecosystem director